Cambridge Investment Research Advisors
KDNY

Cambridge Investment Research Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Cambridge Investment Research Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,400
Closed -$29K – 2802
2020
Q3 		$29K Buy
+2,400
New +$32.2K ﹤0.01% 2479

Other funds holding KDNY

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cambridge Investment Research Advisors's KDNY Position: Q4 2020 in Review

Cambridge Investment Research Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2020, closing a stake of 2,400 shares — an estimated $29K sold.

Cambridge Investment Research Advisors first reported a position in KDNY in Q3 2020 and held it in 1 quarter. The position peaked at $29K in Q3 2020. 77 funds tracked by Wall St. Rank hold KDNY as of Q4 2020.

  • Cambridge Investment Research Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,400 Chinook Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $29K.
  • Cambridge Investment Research Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $29K in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2020, filed 4 Feb 2021.